Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1985 Oct;20(2):137–144. doi: 10.1007/BF00205680

A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity

Wei-Zen Wei 1,✉, Richard J Massey 2, Gloria H Heppner 1
PMCID: PMC11038338  PMID: 3899350

Abstract

A 3-dimensional tumor growth inhibition assay [18] has been adapted to test the cytotoxic activity of a panel of monoclonal antibodies directed to various antigenic determinants on the surface of mouse mammary tumor cells. Target cells can be prepared from either cultured cells or from pieces of fresh tumor. Antibody and complement are added when cells are growing actively and cell growth can be measured, non destructively, over a 7–10-day period. Effective diffusion of antibody through collagen gel and binding to target cells embedded in the gel is demonstrated by indirect immunofluorescent staining. The specificity of monoclonal antibody AMT 101 cytotoxicity for mouse mammary tumor cells is the same in trypan blue exclusion assays of single-cell suspensions as in collagen gel assays, with complete killing seen in the collagen gel assay only. The collagen gel assay allows the testing of repeated treatments in vitro, as well as combined treatment with multiple antibodies. It also allows cell-cell interaction and preserves all cell components in the tumor. The collagen gel assay has potential as a method of predicting the outcome of monoclonal antibody treatment of solid tumors.

Keywords: Monoclonal Antibody, Target Cell, Trypan Blue, Immunofluorescent Staining, Effective Diffusion

Références

  • 1.Ceriani RL, Peterson JA, Lee JY, Moncada R, Blank EW. Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Somatic Cell Genet. 1983;9:415. doi: 10.1007/BF01543043. [DOI] [PubMed] [Google Scholar]
  • 2.Chen TR. In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res. 1977;104:255. doi: 10.1016/0014-4827(77)90089-1. [DOI] [PubMed] [Google Scholar]
  • 3.Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA. 1981;78:3199. doi: 10.1073/pnas.78.5.3199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Colcher D, Horan Hand P, Nuti M, Schlom J. Differential binding to human mammary and non-mammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen. Cancer Invest. 1983;1:27. doi: 10.3109/07357908309042415. [DOI] [PubMed] [Google Scholar]
  • 5.Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978;38:3174. [PubMed] [Google Scholar]
  • 6.Galfre G, Milstein C, Wright B. Rat × Rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature. 1979;277:131. doi: 10.1038/277131a0. [DOI] [PubMed] [Google Scholar]
  • 7.Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H. Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA. 1980;77:4539. doi: 10.1073/pnas.77.8.4539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:462. doi: 10.1126/science.560061. [DOI] [PubMed] [Google Scholar]
  • 9.Heppner GH. The challenge of tumor heterogeneity. Commentaries of research in breast disease. 1979;1:117. [Google Scholar]
  • 10.Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J. Influence of special configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res. 1985;45:833. [PubMed] [Google Scholar]
  • 11.Imai K, Ng AK, Ferrone S. Monoclonal antibodies to human melanoma associated antigens. J Natl Cancer Inst. 1981;66:489. [PubMed] [Google Scholar]
  • 12.Kishida K, Masuho Y, Saito M, Takeshi H, Hiroshi F. Ricin A-chain conjugated with monoclonal anti-L1210 antibody- in vitro and in vivo antitumor activity. Cancer Immunol Immunother. 1983;16:93. doi: 10.1007/BF00199238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 14.Mahoney KH, Fulton AM, Heppner GH. Tumor-associated macrophages of mouse mammary tumors. 11. Differential distribution of macrophages from metastatic and nonmetastatic tumors. J Immunol. 1983;131:2079. [PubMed] [Google Scholar]
  • 15.Massey RJ, Schochetman G. Topographical analysis of viral epitopes using monoclonal antibodies: mechanism of virus neutralization. Virology. 1981;115:20. doi: 10.1016/0042-6822(81)90085-4. [DOI] [PubMed] [Google Scholar]
  • 16.Mew D, Wat CK, Towers GHN, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol. 1983;130:1473. [PubMed] [Google Scholar]
  • 17.Miller BE, Miller FR, Heppner GH. Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res. 1981;41:4378. [PubMed] [Google Scholar]
  • 18.Miller BE, Miller FR, Heppner GH. Rational basis for chemotherapy. New York: Alan R. Liss, Inc.; 1983. Development of a drug-sensitivity assay for heterogeneous tumors based on growth in 3-dimensional collagen gels; p. 107. [Google Scholar]
  • 19.Miller BE, Miller FR, Heppner GH. Assessing tumor drug sensitivity by a new in vitro assay which preserves tumor heterogeneity and subpopulation interactions. J Cell Physiol. 1984;3:105. doi: 10.1002/jcp.1041210413. [DOI] [PubMed] [Google Scholar]
  • 20.Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med. 1982;306:517. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
  • 21.Neville DM, Houle RJ. Monoclonal antibody-ricin or ricin-A chain hybrids kinetic analysis of cell killing for tumor therapy. Immunol Rev. 1982;62:75. doi: 10.1111/j.1600-065x.1982.tb00390.x. [DOI] [PubMed] [Google Scholar]
  • 22.Nuti M, Teramoto YA, Mariana-Costantini R, Horan Hand P, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor associated antigen in human mammary carcinoma cell populations. Int J Cancer. 1982;29:539. doi: 10.1002/ijc.2910290509. [DOI] [PubMed] [Google Scholar]
  • 23.Ratner S, Heppner GH. Tumor microenvironmental influences upon locomotion of T-cell subsets. Proc Am Assoc Cancer Res. 1984;25:275. [Google Scholar]
  • 24.Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts D, Moon TE. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. New Engl J Med. 1978;298:1321. doi: 10.1056/NEJM197806152982401. [DOI] [PubMed] [Google Scholar]
  • 25.Selby P, Buick RN, Tannock I. A critical appraisal of the “human tumor stem-cell assay”. New Engl J Med. 1983;308:129. doi: 10.1056/NEJM198301203080304. [DOI] [PubMed] [Google Scholar]
  • 26.Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature. 1981;294:171. doi: 10.1038/294171a0. [DOI] [PubMed] [Google Scholar]
  • 27.Wei WZ. An in vitro antibody-mediated cytotoxicity test for solid tumors actively growing in 3-dimensional collagen matrix. Proc Am Assoc Cancer Res. 1984;25:247. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES